Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06492317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 9, 2024 (before its estimated July 6, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma
Trial Details
NCT Number NCT06492317
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions
(from sponsor)		 HER2-positive Gastric Cancer
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov